Neutralizing Antibody and T-Cell Responses against SARS-CoV-2 Wild-Type and Variants of Concern in Chronic Obstructive Pulmonary Disease Subjects after ChAdOx-1/ChAdOx-1 Homologous Vaccination: A Preliminary Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Materials
2.2. Study Design and Participants
2.3. Study Procedures
2.4. Assay for Neutralizing Antibodies
2.5. Assay for CD4 and CD8 T Responses
2.6. Statistical Analysis
3. Results
3.1. Study Cohort
3.2. Neutralizing Antibody Responses
3.3. T-Cell Responses
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Alqahtani, J.S.; Oyelade, T.; Aldhahir, A.M.; Alghamdi, S.M.; Almehmadi, M.; Alqahtani, A.S.; Quaderi, S.; Mandal, S.; Hurst, J.R. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: A rapid systematic review and meta-analysis. PLoS ONE 2020, 15, e0233147. [Google Scholar] [CrossRef] [PubMed]
- Saheb Sharif-Askari, N.; Saheb Sharif-Askari, F.; Alabed, M.; Temsah, M.H.; Al Heialy, S.; Hamid, Q.; Halwani, R. Airways expression of SARS-CoV-2 receptor, ACE2, and TMPRSS2 is lower in children than adults and increases with smoking and COPD. Mol. Ther. Methods Clin. Dev. 2020, 18, 1–6. [Google Scholar] [CrossRef] [PubMed]
- Halpin, D.M.G.; Criner, G.J.; Papi, A.; Singh, D.; Anzueto, A.; Martinez, F.J.; Agusti, A.A.; Vogelmeier, C.F. Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care. Med. 2021, 203, 24–36. [Google Scholar] [CrossRef]
- Nath, K.D.; Burel, J.G.; Shankar, V.; Pritchard, A.L.; Towers, M.; Looke, D.; Davies, J.M.; Upham, J.W. Clinical factors associated with the humoral immune response to influenza vaccination in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2014, 9, 51–56. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Parpaleix, A.; Boyer, L.; Wiedemann, A.; Lacabaratz, C.; Margarit, L.; Enouf, V.; Le Corvoisier, P.; Lino, A.; Covali-Noroc, A.; Housset, B.; et al. Impaired humoral and cellular immune responses to influenza vaccination in chronic obstructive pulmonary disease patients. J. Allergy Clin. Immunol. 2017, 140, 1754–1757.e6. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Burel, J.G.; Nath, K.; Pritchard, A.L.; White, O.J.; Davies, J.M.; Towers, M.; Looke, D.; Upham, J.W. Evaluation of immune responses to influenza vaccination in chronic obstructive pulmonary disease. J. Vaccines Vaccin. 2012, S4, 001. [Google Scholar]
- Harboe, Z.B.; Hamm, S.R.; Pérez-Alós, L.; Sivapalan, P.; Priemé, H.; Wilcke, T.; Kjeldgaard, P.; Shaker, S.; Svorre Jordan, A.; Møller, D.L.; et al. Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases. BMJ. Open Respir. Res. 2022, 9, e001268. [Google Scholar] [CrossRef]
- Pelletier, É.; Desmeules, P.; Lacasse, Y.; Tanguay, S.; Milot, J.; Morissette, M.C.; Maltais, F. Antibody response to severe acute respiratory syndrome coronavirus-2 vaccination in COPD: A cohort study. Chronic Obstr. Pulm. Dis. 2022, 9, 591–595. [Google Scholar] [CrossRef]
- Southworth, T.; Jackson, N.; Singh, D. Airway immune responses to COVID-19 vaccination in COPD patients and healthy subjects. Eur. Respir. J. 2022, 60, 2200497. [Google Scholar] [CrossRef]
- Graham, B.L.; Steenbruggen, I.; Miller, M.R.; Barjaktarevic, I.Z.; Cooper, B.G.; Hall, G.L.; Hallstrand, T.S.; Kaminsky, D.A.; McCarthy, K.; McCormack, M.C.; et al. Standardization of spirometry 2019 update. An official american thoracic society and european respiratory society technical statement. Am. J. Respir. Crit. Care Med. 2019, 200, e70–e88. [Google Scholar] [CrossRef]
- Knudson, R.J.; Lebowitz, M.D.; Holberg, C.J.; Burrows, B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am. Rev. Respir. Dis. 1983, 127, 725–734. [Google Scholar] [PubMed]
- Mohseni Afshar, Z.; Babazadeh, A.; Janbakhsh, A.; Mansouri, F.; Sio, T.T.; Sullman, M.J.M.; Carson-Chahhoud, K.; Hosseinzadeh, R.; Barary, M.; Ebrahimpour, S. Coronavirus disease 2019 (COVID-19) vaccination recommendations in special populations and patients with existing comorbidities. Rev. Med. Virol. 2022, 32, e2309. [Google Scholar] [CrossRef] [PubMed]
- Liwsrisakun, C.; Pata, S.; Laopajon, W.; Takheaw, N.; Chaiwong, W.; Inchai, J.; Pothirat, C.; Bumroongkit, C.; Deesomchok, A.; Theerakittikul, T.; et al. Neutralizing antibody and T cell responses against SARS-CoV-2 variants of concern following ChAdOx-1 or BNT162b2 boosting in the elderly previously immunized with CoronaVac vaccine. Immun. Ageing 2022, 19, 24. [Google Scholar] [CrossRef]
- Chau, N.V.V.; Nguyet, L.A.; Truong, N.T.; Toan, L.M.; Dung, N.T.; Hung, L.M.; Nhan, M.T.; Man, D.N.H.; Ngoc, N.M.; Thao, H.P.; et al. Immunogenicity of oxford-astrazeneca COVID-19 vaccine in vietnamese health-care workers. Am. J. Trop. Med. Hyg. 2022, 106, 556–561. [Google Scholar] [CrossRef] [PubMed]
- Brockman, M.A.; Mwimanzi, F.; Lapointe, H.R.; Sang, Y.; Agafitei, O.; Cheung, P.K.; Ennis, S.; Ng, K.; Basra, S.; Lim, L.Y.; et al. Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults. J. Infect. Dis. 2022, 225, 1129–1140. [Google Scholar] [CrossRef]
- Moss, P. The T cell immune response against SARS-CoV-2. Nat. Immunol. 2022, 23, 186–193. [Google Scholar] [CrossRef]
- Young, A. T cells in SARS-CoV-2 infection and vaccination. Ther. Adv. Vaccines Immunother. 2022, 10, 25151355221115011. [Google Scholar] [CrossRef]
- Li, Q.; Wang, Y.; Sun, Q.; Knopf, J.; Herrmann, M.; Lin, L.; Jiang, J.; Shao, C.; Li, P.; He, X.; et al. Immune response in COVID-19: What is next? Cell Death. Differ. 2022, 29, 1107–1122. [Google Scholar] [CrossRef]
- Zhu, X.; Zhu, J. CD4 T helper cell subsets and related human immunological disorders. Int. J. Mol. Sci. 2020, 21, 8011. [Google Scholar] [CrossRef]
- Topham, D.J.; Tripp, R.A.; Doherty, P.C. CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J. Immunol. 1997, 159, 5197–5200. [Google Scholar]
- Ratner, A.; Clark, W.R. Role of TNF-alpha in CD8+ cytotoxic T lymphocyte-mediated lysis. J. Immunol. 1993, 150, 4303–4314. [Google Scholar] [PubMed]
- Kotov, D.I.; Kotov, J.A.; Goldberg, M.F.; Jenkins, M.K. Many Th cell subsets have Fas ligand-dependent cytotoxic potential. J. Immunol. 2018, 200, 2004–2012. [Google Scholar] [CrossRef] [PubMed]
- Wilkinson, T.M.A.; Schembri, S.; Brightling, C.; Bakerly, N.D.; Lewis, K.; MacNee, W.; Rombo, L.; Hedner, J.; Allen, M.; Walker, P.P.; et al. Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial. Vaccine 2019, 37, 6102–6111. [Google Scholar] [CrossRef] [PubMed]
- Yang, C.X.; Tomchaney, M.; Landecho, M.F.; Zamacona, B.R.; Marin Oto, M.; Zulueta, J.; Malo, J.; Knoper, S.; Contoli, M.; Papi, A.; et al. Lung spatial profiling reveals a T cell signature in COPD patients with fatal SARS-CoV-2 infection. Cells 2022, 11, 1864. [Google Scholar] [CrossRef]
- Lafon, E.; Diem, G.; Witting, C.; Zaderer, V.; Bellmann-Weiler, R.M.; Reindl, M.; Bauer, A.; Griesmacher, A.; Fux, V.; Hoermann, G.; et al. Potent SARS-CoV-2-specific T cell immunity and low anaphylatoxin levels correlate with mild disease progression in COVID-19 patients. Front. Immunol. 2021, 12, 684014. [Google Scholar] [CrossRef] [PubMed]
- Tan, A.T.; Linster, M.; Tan, C.W.; Le Bert, N.; Chia, W.N.; Kunasegaran, K.; Zhuang, Y.; Tham, C.Y.L.; Chia, A.; Smith, G.J.D.; et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell. Rep. 2021, 34, 108728. [Google Scholar] [CrossRef]
- Gao, L.; Zhou, J.; Yang, S.; Wang, L.; Chen, X.; Yang, Y.; Li, R.; Pan, Z.; Zhao, J.; Li, Z.; et al. The dichotomous and incomplete adaptive immunity in COVID-19 patients with different disease severity. Signal Transduct. Target. Ther. 2021, 6, 113. [Google Scholar] [CrossRef]
- Zhang, L.; Li, R.; Song, G.; Scholes, G.D.; She, Z.S. Impairment of T cells’ antiviral and anti-inflammation immunities may be critical to death from COVID-19. R. Soc. Open. Sci. 2021, 8, 211606. [Google Scholar] [CrossRef]
- Zenarruzabeitia, O.; Astarloa-Pando, G.; Terrén, I.; Orrantia, A.; Pérez-Garay, R.; Seijas-Betolaza, I.; Nieto-Arana, J.; Imaz-Ayo, N.; Pérez-Fernández, S.; Arana-Arri, E.; et al. T cell activation, highly armed cytotoxic cells and a shift in monocytes CD300 receptors expression is characteristic of patients with severe COVID-19. Front. Immunol. 2021, 12, 655934. [Google Scholar] [CrossRef]
- Lacedonia, D.; Scioscia, G.; Santomasi, C.; Fuso, P.; Carpagnano, G.E.; Portacci, A.; Mastroianni, F.; Larizza, G.; Sabato, E.; Profilo, E.; et al. Impact of smoking, COPD and comorbidities on the mortality of COVID-19 patients. Sci. Rep. 2021, 11, 19251. [Google Scholar] [CrossRef]
- Kim, Y.; An, T.J.; Park, Y.B.; Kim, K.; Cho, D.Y.; Rhee, C.K.; Yoo, K.H. Chronic obstructive pulmonary disease is not associated with a poor prognosis in COVID-19. Tuberc. Respir. Dis. 2022, 85, 74–79. [Google Scholar] [CrossRef] [PubMed]
- Jeong, J.S.; Kim, J.S.; You, Y.S.; Yeom, S.W.; Lee, Y.C. COPD is a risk factor for COVID-19, but does not confer increased severity of the disease. Respir. Med. 2021, 189, 106640. [Google Scholar] [CrossRef] [PubMed]
- Turan, O.; Arpınar Yigitbas, B.; Turan, P.A.; Mirici, A. Clinical characteristics and outcomes of hospitalized COVID-19 patients with COPD. Expert. Rev. Respir. Med. 2021, 15, 1069–1076. [Google Scholar] [CrossRef] [PubMed]
Characteristics | COPD (N = 8) | Healthy Elderly (N = 8) | p-Value |
---|---|---|---|
Age (years) | 77.1 ± 6.5 | 73.5 ± 4.8 | 0.224 |
Male (sex) | 7 (87.5) | 7 (87.5) | 1.000 |
Height (cm) | 159.9 ± 7.2 | 165.1 ± 9.8 | 0.240 |
Body weight (kg) | 54.9 ± 10.1 | 62.0 ± 8.9 | 0.157 |
Body mass index (kg/m2) | 21.6 ± 5.0 | 22.8 ± 2.9 | 0.593 |
Underlying diseases | 0.721 | ||
Cardiovascular | 2 (25.0) | 2 (25.0) | |
Metabolic | 0 (0.0) | 1 (12.5) | |
Cardiovascular + Metabolic | 2 (25.0) | 1 (12.5) | |
None | 4 (50.0) | 4 (50.0) | |
Smoking status | 0.026 | ||
Non-smoker | 0 (0.0) | 5 (62.5) | |
Ex-smoker | 8 (100.0) | 3 (37.5) | |
Smoking pack-year (Median, IQR) | 45.0 (25.3, 50.0) | 0.0 (0.0, 30.0) | 0.012 |
Spirometry results | N.A. | ||
FVC | 2.49 ± 0.58 | ||
% predicted of FVC | 96.9 ± 23.7 | ||
FEV1 | 1.38 ± 0.45 | ||
% predicted of FEV1 | 69.7 ± 27.7 | ||
Ratio of FEV1/FVC | 54.4 ± 9.9 | ||
Inhaled medication for COPD | N.A. | ||
LAMA | 1 (12.5) | ||
LABA + LAMA | 1 (12.5) | ||
ICS + LABA | 1 (12.5) | ||
ICS + LAMA | 1 (12.5) | ||
ICS + LABA + LAMA | 4 (50.0) |
COPD | Healthy Elderly | |||||
---|---|---|---|---|---|---|
Before (n = 8) | 4 Weeks (n = 8) | 12 Weeks (n = 7) | Before (n = 8) | 4 Weeks (n = 8) | 12 Weeks (n = 8) | |
Wild-type | 12.6 (7.1, 14.3) | 84.0 * (73.2, 90.7) | 78.1 *,# (61.5, 82.9) | 4.7 (3.7, 11.2) | 89.4 * (51.9, 95.2) | 69.2 *,# (39.5, 79.7) |
Alpha (B.1.1.7) | 15.9 (13.2, 17.1) | 71.2 * (59.1, 88.4) | 57.9 *,# (40.3, 68.7) | 10.5 (7.4, 15.1) | 78.6 * (43.4, 90.8) | 50.5 *,# (24.5, 59.0) |
Beta (B.1.351) | 17.0 (11.5, 19.1) | 55.9 * (40.7, 74.2) | 34.6 # (16.9, 61.7) | 14.9 (14.6, 16.1) | 67.7 * (40.3, 83.7) | 48.9 *,# (31.7, 63.9) |
Delta (B.1.617.2) | 15.2 (13.7, 16.9) | 77.8 * (50.4, 91.9) | 64.5 *,# (51.3, 83.8) | 14.5 (9.7, 15.9) | 88.6 * (57.2, 94.8) | 63.8 *,# (31.9, 73.4) |
Omicron BA.2 | 3.9 (−0.4, 6.2) | 27.6 * (11.9, 41.9) | 26.2 * (17.1, 31.7) | 14.0 (6.2, 19.6) | 27.8 (11.1, 52.6) | 17.5 (10.9, 38.8) |
Omicron BA.4&BA.5 | 7.9 (6.3, 10.3) | 21.8 * (12.7, 38.3) | 22.8 * (20.7, 29.7) | 16.5 (13.9, 17.5) | 31.3 * (23.0, 41.7) | 26.2 *,# (17.9, 33.9) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Chaiwong, W.; Takheaw, N.; Laopajon, W.; Pata, S.; Duangjit, P.; Inchai, J.; Pothirat, C.; Bumroongkit, C.; Deesomchok, A.; Theerakittikul, T.; et al. Neutralizing Antibody and T-Cell Responses against SARS-CoV-2 Wild-Type and Variants of Concern in Chronic Obstructive Pulmonary Disease Subjects after ChAdOx-1/ChAdOx-1 Homologous Vaccination: A Preliminary Study. Vaccines 2022, 10, 2176. https://doi.org/10.3390/vaccines10122176
Chaiwong W, Takheaw N, Laopajon W, Pata S, Duangjit P, Inchai J, Pothirat C, Bumroongkit C, Deesomchok A, Theerakittikul T, et al. Neutralizing Antibody and T-Cell Responses against SARS-CoV-2 Wild-Type and Variants of Concern in Chronic Obstructive Pulmonary Disease Subjects after ChAdOx-1/ChAdOx-1 Homologous Vaccination: A Preliminary Study. Vaccines. 2022; 10(12):2176. https://doi.org/10.3390/vaccines10122176
Chicago/Turabian StyleChaiwong, Warawut, Nuchjira Takheaw, Witida Laopajon, Supansa Pata, Pilaiporn Duangjit, Juthamas Inchai, Chaicharn Pothirat, Chaiwat Bumroongkit, Athavudh Deesomchok, Theerakorn Theerakittikul, and et al. 2022. "Neutralizing Antibody and T-Cell Responses against SARS-CoV-2 Wild-Type and Variants of Concern in Chronic Obstructive Pulmonary Disease Subjects after ChAdOx-1/ChAdOx-1 Homologous Vaccination: A Preliminary Study" Vaccines 10, no. 12: 2176. https://doi.org/10.3390/vaccines10122176